This is one where due diligence can go a LONG way. While some...

This is one where due diligence can go a LONG way. While some may look at it as very early stage (only phase 1) and decide it's overvalued, others who have done the research know that it's actually playing like a phase 2 stage company heading towards that pivotal phase 3. Because CHMs phase 2 will most likely be a registration trial it's actually a lot more mature than most might think (and value). I see anything around the $100m MC as incredible value considering if trial data shows any strong efficacy during phase 1 it might get considerable interest from big pharma before phase 2 has even initiated. I don't think either that the market has valued in the asset acquired from Penn State that will hit phase 1 next year. Exciting times ahead and can't wait to hear data updates at the upcoming conference.